Table 1.
Patients’ characteristics according to CXCR4 mutational status.
| Characteristic | All participants (n = 30) |
CXCR4 WT (n = 16) |
CXCR4 MUT (n = 14) |
p |
|---|---|---|---|---|
| Age | ||||
| At WM diagnosis, median (range)—years | 64 (43–81) | 63 (43–81) | 64 (43–71) | 0.93 |
| At ibrutinib initiation, median (range)—years | 67 (43–83) | 67 (43–83) | 67 (43–75) | 0.87 |
| >65 years at ibrutinib initiation (%) | 19 (63) | 10 (63%) | 9 (64%) | 1.00 |
| Sex | ||||
| Male (%) | 23 (77) | 12 (75%) | 11 (79%) | 1.00 |
| Female (%) | 7 (23) | 4 (25%) | 3 (21%) | |
| Serum IgM level | ||||
| Median (range)—mg/dl | 4370 (844–10,321) | 3928 (858–10,321) | 5294 (844–7450) | 0.58 |
| ≥4000 mg/dl (%) | 16 (53) | 8 (50%) | 8 (57%) | 0.73 |
| Hemoglobin level | ||||
| Median (range)—g/dl | 10.3 (7.5–14.4) | 10.1 (8.6–14.4) | 10.6 (7.5–13.5) | 0.60 |
| ≤11.5 g/dl (%) | 23 (77) | 13 (81%) | 10 (71%) | 0.42 |
| Platelet count | ||||
| Median (range)—×109/L | 247 (59–491) | 288 (129–418) | 199 (59–491) | 0.13 |
| ≤100 × 109/L (%) | 2 (7) | 0 (0%) | 2 (14%) | 0.21 |
| Serum beta-2-microglobulin level | ||||
| Median (range)—g/dl | 3.8 (2–7.6) | 4.2 (2.3–6.9) | 3.4 (2–7.6) | 0.07 |
| >3 g/dl (%) | 22 (73) | 13 (81%) | 9 (64%) | 0.42 |
| IPSSWM score | ||||
| Low risk (%) | 5 (17) | 3 (19%) | 2 (14%) | 0.39 |
| Intermediate risk (%) | 11 (37) | 4 (25%) | 7 (50%) | |
| High risk (%) | 14 (47) | 9 (56%) | 5 (36%) | |
| Bone marrow involvement | ||||
| Median (range) - % | 65 (5–95) | 60 (5–95) | 70 (10–90) | 0.57 |
| ≥60% (%) | 22 (73) | 10 (63%) | 12 (86%) | 0.23 |
| Extramedullary disease | ||||
| Adenopathy ≥1.5 cm (%) | 10 (33) | 8 (50%) | 2 (14%) | 0.04 |
| Splenomegaly ≥15 cm (%) | 5 (17) | 4 (25%) | 1 (7%) | 0.34 |
| Time from WM diagnosis to ibrutinib | ||||
| <12 months (%) | 16 (53) | 10 (63%) | 6 (43%) | 0.46 |
| ≥12 months (%) | 14 (47) | 6 (38%) | 8 (57%) | |
WM Waldenstrom macroglobulinemia, IPSSWM International Prognostic Scoring System for WM, WT wildtype, MUT mutated.